Footnotes

• Contributors RKR, PI and CP all contributed equally to the idea and generation of the article. All authors have seen and approved the final draft.

• Funding RKR has received support from a Medical Research Council (MRC) patient research cohorts initiative grant (G0800675) for PICTS. RKR is supported by an NHS Research Scotland career fellowship award. The work of the IBD team at Yorkhill is supported by the Catherine McEwan Foundation and the Yorkhill IBD fund.

• Competing interests RKR has received speaker's fees, travel support or participated in medical board meetings with MSD Immunology, Abbott, Dr Falk, Nestle, Janssen, NAPP and Ferring Pharmaceuticals. PI has received honoraria for acting in an advisory capacity or speaking on behalf of Warner Chilcott, Shire, Ferring, Tillotts Pharma, Vifor, Pharmacosmos, Takeda, MSD, Abbvie and Genentech. CP has received honoraria for acting in an advisory capacity or speaking on behalf of Abbvie, Falk, Ferring, Hospira, MSD, Napp, Shire, Takeda, Tillotts and Warner Chilcott.

• Provenance and peer review Not commissioned; externally peer reviewed.